NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support **17 Dec 2015**

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.***

Important notices

- **Application Missteps—Poor Writing and Presentation. Faltering in writing and presentation could keep your reviewers from feeling enthusiastic about the application you've spent much time and effort preparing. See what stumbling blocks you could run into and how to steer clear of them.**
- **Findings of Research Misconduct (NOT-OD-16-040)**
- **Notice of Pre-application Webinar for Small-Cell Lung Cancer (SCLC) Consortium Covered by PAR-16-049, PAR-16-050 and PAR-16-051 (NOT-CA-16-015)**
- **Notice (NOT-AI-16-021) of Mycobacterium Tuberculosis (Mtb) Quality Assessment Program NIAID-DAIDS-NIHAI2015048 with the purpose to provide a new resource to assess the ability of 25-30 laboratories located both in the United States (U.S.) and outside (non-U.S.) to accurately and reliably perform Mtb testing to diagnose active and latent Mtb infection, monitor disease progression, and assess treatment response and vaccine efficacy in direct support of clinical trials.**
- **ASSIST Now an Option for All NIH Competing Grant Applications and Some Post-award Administrative Actions (NOT-OD-16-042)**
- **Notice of Additional Participation in PAR-16-052 "Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21)" (NOT-TW-16-002)**

1. Operations Research (Implementation Science) for Strengthening Program Implementation through the Presidents Emergency Plan for AIDS Relief (PEPFAR)

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** RFA-GH-16-005

Type: Cooperative Agreement. **Application Due Date:** Mar 25, 2016 Apply by 5:00 PM ET. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This FOA will directly support investigators working at public and nonprofit private institutions and agencies in PEPFAR-supported countries for the conduct of operations research (implementation science) essential for strengthening activities in selected areas of prevention, care, and treatment of HIV/AIDS. The overall purpose of these research activities is to yield knowledge that will help to optimize the delivery of services and maximize the population-level impact of HIV/AIDS prevention, care, and treatment services provided in PEPFAR-supported countries.

Budget: The Centers for Disease Control and Prevention is planning to fund 5 projects. Estimated Total Program Funding: $5,000,000. Award Ceiling: $500,000. Award Floor: $100,000

2. Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (RFA-DA-16-012) **Type:** **RO1**

Application Due Date: March 2, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The goal of this Funding Opportunity Announcement (FOA) is to stimulate innovative hypothesis-driven research to enhance our understanding of the role of epigenomic or non-coding RNA regulatory mechanisms in HIV/AIDS infection or disease trajectory in combination with substance use or abuse. We are particularly interested in understanding regulatory mechanisms that influence selection and regulation of HIV sites of integration in the host genome. A deeper understanding of these mechanisms could lead to novel approaches for monitoring latent HIV in cellular reservoirs, especially in the central nervous system. Ultimately, research in this area could enable the identification of molecular targets that could be manipulated either to eliminate or permanently repress HIV in cellular reservoirs.

Budget: NIDA intends to commit $3 million dollars in FY 2016 to fund 5-8 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Project periods may not exceed 5 years.

3. Fogarty Global Injury and Trauma Research Training Program

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (RFA-TW-16-001) **Type: D43**

Application Due Date: February 24, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The overall objective of this Funding Opportunity Announcement (FOA) is to strengthen injury and trauma research capacity at academic institutions in low- and middle-income countries (LMICs) through support for research training programs. The training program should:

- Provide in depth training in research design, methods, and analytic techniques appropriate for the proposed research area(s);
- Support trainees to conduct mentored research using state-of-the-art methods;
- Provide training in scientific presentation and publication;
- Support trainees to obtain advanced degrees (Master's or Ph.D.) in injury and trauma research; and
- Support research faculty/mentors to strengthen injury and trauma research capacity at LMIC institutions, and to contribute to national and global injury research initiatives and networks.

Budget: Applicants may request up to $250,000 per year (direct costs). The maximum project period is 5 years.

4. Ancillary Studies to the NIDDK Intestinal Stem Cell Consortium

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (PA-16-062) **Type: RO1**

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages applications to conduct ancillary studies to the NIDDK Intestinal Stem Cell Consortium (ISCC). Studies will make use of consortium collaborations, techniques or resources to accelerate research into intestinal stem cells. The proposed ancillary study must be designed to advance the scientific research mission of the NIDDK by focusing on diseases and areas of interest to the Institute and should be commensurate with the interests and intent of the ISCC.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Novel Assays to Address Translational Gaps in Treatment Development

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (PAR-16-065) **Type: UG3/UH3**

Application Due Date: March 8, 2016 , June 23, 2016, October 24, 2016, February 23, 2017, June 23, 2017, October 24, 2017, February 23, 2018, June 26, 2018, October 24, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The FOA will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to specific chemical, physiological, or behavioral manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The UG3 period may not exceed 2 years, the UH3 period may not exceed 3 years. The total duration of the UG3 and UH3 phases may not exceed 4 years.

6. Behavioral and Integrative Treatment Development Program

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (PA-16-072) **Type: RO1**

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this FOA is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) drug abuse treatment and adherence interventions for use in primary care; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat chronic pain. Research of interest includes but is not limited to Stage II and Stage III efficacy research.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

7. Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (PA-16-076) **Type:** **RO1**
(PA-16-075) **R21**

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R21) applications from institutions/ organizations that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for Substance Use Disorders (SUDs). Clinical trials evaluating the efficacy of medications to treat SUDs are limited by two major issues: a) uncertainty in assessing the level of a subject's adherence to the trial medication regimen and b) an inability to accurately and quantitatively monitor the frequency and level of a subject's illicit drug exposure). This FOA encourages the development of systems that address at least one of these issues. Applications submitted to this opportunity should focus around an outpatient clinical trial, with or without preclinical system development studies. Applications not seeking to test a minimally invasive bioassay system in a clinical trial are not appropriate for this opportunity.

Budget: RO1-Total direct costs budget should be less than $500,000 per year. The maximum project period is 3 years**. R21-**Application budgets are limited to $275,000 in direct costs over two years with no more than $200,000 in either year. The maximum project period is 2 years.

9. NIDCR Small Research Grants for Data Analysis and Statistical Methodology Applied to Genome-wide Data

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (PAR-16-070) **Type:** **RO3**

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this FOA is to provide support for meritorious research projects that involve statistical analysis of existing genome-wide data (e.g. genome-wide SNP genotyping; DNA sequencing; transcriptomic, metagenomic, epigenomic, or gene expression data) relevant to human dental, oral, or craniofacial conditions or traits. Development of statistical methodology appropriate for analyzing genome-wide data, relevant to human dental, oral, or craniofacial conditions or traits, may also be proposed.

Budget: The combined budget for direct costs for the two year project period may not exceed $200,000. No more than $200,000 direct costs may be requested in any single year. A project duration of up to two years may be requested.

NIH National Institutes of Health
Turning Discovery Into Health

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete Glossary and acronym list of NIH Terms

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa Coetsee*** • Tel: 9838 • Email: **cdevries@sun.ac.za**